New Triple-Threat attack on Tough-to-Treat leukemias
NCT ID NCT06401603
Summary
This early-stage study aims to find safe and effective doses of a new three-drug combination for adults with advanced forms of two specific leukemias. The trial will enroll about 30 people whose disease has not responded well to prior standard treatments. Researchers will test the safety of combining the drugs decitabine, lisaftoclax, and olverembatinib and see if they can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.